Skip to main content
SpringerLink
Log in

Die Differentialtherapie des Typ-II-Diabetes

  • Conference paper
Verhandlungen der Deutschen Gesellschaft für Innere Medizin

Part of the book series: Verhandlungen der Deutschen Gesellschaft für Innere Medizin ((VDGINNERE,volume 92))

  • 34 Accesses

Zusammenfassung

Im Gegensatz zum Insulin-abhängigen Typ-I-Diabetes ist der primär nicht Insulin-abhängige Typ-II-Diabetes bezüglich des Ausmaßes der gestörten β-Zellfunktion sowie der Insulin Wirkung am Rezeptor, bzw. des Postrezeptordefektes heterogener und inhomogener als angenommen [108].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Althoff P-H, Faßbinder W, Neubauer M, Koch KM, Schöfflin K (1978) Hämodialyse bei der Behandlung der Biguanid-induzierten Lactatazidose. Dtsch Med Wschr 103:61

    PubMed  CAS  Google Scholar 

  2. Althoff P-H, Haupt E, Schöfflin K (1985) Prädiktoren des Sulfonylharnstoffversagens, 5. Bad Neuenahrer Diabetes-Tagung 1985. In: Drost H, Gries FA, Jahnke K (eds) Der nicht-insulinabhängige Diabetes mellitus (Typ II). Schattauer, Stuttgart New York

    Google Scholar 

  3. Asplund K, Wiholm BE, Lithner F (1983) Glibenclamid-associated hypoglycaemia: A report on 57 cases. Diabetologia 24:412–417

    PubMed  CAS  Google Scholar 

  4. Bachmann W, Sieger C, Lotz N (1983) Kombinationstherapie Insulin/Glibenclamid bei Typ-II-Diabetikern mit relativer Insulinresistenz. In: Bachmann W, Mehnert H (Hrsg) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, Basel, S 145

    Google Scholar 

  5. Bachmann W (1982) Insulin plus Sulfonylharnstoff-eine (un)mögliche Kombination? Dtsch Med Wschr 5:163

    Google Scholar 

  6. Bachmann W, Lotz N, Mehnert H (1984) Kombinationstherapie Insulin/Sulfonylharnstoff (KOMB) bei Typ-II-Diabetikern mit Sekundärversagen einer Sulfonylharnstofftherapie. Akt Endokr 5:78

    Google Scholar 

  7. Bachmann W, Mehnert H (Hrsg) (1983) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, Basel

    Google Scholar 

  8. Beck-Nielson H, Pedersen O, Lindskov HO (1979) Increased insulin sensitivity and cellular insulin binding to obese diabetics following treatment with glibenclamid. Acta endocr (Kbh.) 90:451

    Google Scholar 

  9. Beck-Nielson H, Hjollund O, Pedersen HO, Richelsen B, Schwartz-Sorensen N (1984) Sulfonylureas improve insulin binding and insulin action in non-insulin-dependent diabetes mellitus. Diabetes Care, Vol 7 (Suppl 1): 100–105

    Google Scholar 

  10. Beckmann R: Pharmakologie und Wirkungsmechanismus der Biguanide beim Tier. In: Oberdisse K (Hrsg) Diabetes mellitus, 5. Aufl., Bd 7, Teil 2B. Springer, Berlin Heidelberg New York, S 951

    Google Scholar 

  11. Beischer W, Keller L, Maas M, Schiefer E, Pfeiffer F (1976) Human C-Peptide. Part I Radioimmunoassay. Klin Wschr 54:709

    PubMed  CAS  Google Scholar 

  12. Beischer W, Schmid M, Kerner W, Keller L, Pfeiffer EF (1979) Feedback inhibition of insulin in healthy and overweight subjects studied by use of an artificial endocrine pancreas. Horm Metab Res (Suppl. Series) 8:97

    CAS  Google Scholar 

  13. Berger M, Standi E (1981) Sulfonylharnstoff in der Diabetestherapie 1981. DMW 106:1443–1446

    CAS  Google Scholar 

  14. Berger W (1979) Present status of biguanides. Pharma-Kritik 1:9

    Google Scholar 

  15. Bieger WP, Dlugosch R, Retenmeier A, Holler HD, Bert H, Schwarz W, Fiehn W(1984) Trial of Sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Klin Wschr 62:13:631

    Google Scholar 

  16. Björntorp P, Krotkiewski M (1985) Exercise treatment in diabetes mellitus (Review). Acta Med Scand 217:3–7

    PubMed  Google Scholar 

  17. Bolinder J, Östman J, Arner P (1985) Reversal of insulin resistance in adipose tissue of non-insulin-dependent diabetes by treatment with diet and sulfonylurea. Acta endocr 108:85–90

    PubMed  CAS  Google Scholar 

  18. Burke BJ, Sheriff J (1980) Stimulation insulin secretion by glibenclamid in insulin dependent diabetics. Acta endocr (Kbh) 98:372

    Google Scholar 

  19. Burke BJ, Hartog M, Waterfield MR (1984) Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide. Acta Endocr 107:70–77

    PubMed  CAS  Google Scholar 

  20. Campbell IW (1984) Metformin and gloibeclamide: comparative risks. Brit med J 289:289

    CAS  Google Scholar 

  21. Caspary WF (1985) Diabetes mellitus: Verzögerung der Kohlenhydrat-Resorption als therapeutisches Prinzip. Dtsch Ärzteblatt 82:1413–1423

    Google Scholar 

  22. Caspary, WF: Sucrose-malabsorption in man after ingestion of a-Glucoide-hydrolase inhibitor

    Google Scholar 

  23. Cohen D, Prezzing V, Vigneri R, Avola R, D’Agatha R, Polosa P (1980) Phenformin increase insulin binding to human cultured breast cancer cells. Diabetes 29:329

    PubMed  CAS  Google Scholar 

  24. Creuzfeld W (Hrsg) (1982) First International Symposium on Acarbos. Effects on carbohydrate and Fat Metabolism. Exerpta Medica, Amsterdam

    Google Scholar 

  25. Davidson JK Newer approaches to diet management of diabetes: caloric control. Med Times 108:35

    Google Scholar 

  26. Daweke H, Braun F, Bach J, Schäfer D (1983) Freisetzung endogener Insulinreserven bei kombinierter Insulin/Sulfonylharnstoff-Therapie von Typ-II-Diabetikern. Akt Endokr 4:177

    Google Scholar 

  27. De Fronzu R, Simonson DC (1984) Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care, Vol. 7 (Suppl 1):72–80

    Google Scholar 

  28. De Fronzo RA, Simonson D, Ferrannini E (1982) Hepatic and peripheral insulin resistance: A common feature of type II (non-insulin-dependent) and type I (insulin-dependent) diabetes mellitus. Diabetologia 23:313–319

    Google Scholar 

  29. De Fronzo RA, Ferrannini E (1982) The pathogenesis of non-insulin dependent diabetes. Medicine 61:125–140

    Google Scholar 

  30. De Lawtwe DE, Moss JM, Tyroler S et al. (1960) Secondary failure of response to tolbutamine treatment. JAMA 171:731

    Google Scholar 

  31. Deutsche Diabetes-Gesellschaft (1983) Orale Diabetes-Therapie mit Medikamenten vom Typ der Sulfonylharnstoffe. Stellungnahme. Diabetologie-Informationen, Heft 2:27

    Google Scholar 

  32. Doar JWH, Thomson ME, Wilde CE, Sewell PFJ (1975) Influence of treatment with diet alone on oral glucose tolerance test and plasma sugar and insulin levels in patients with matuity-onset diabetes mellitus. Lancet 1:1263–1266

    PubMed  CAS  Google Scholar 

  33. Emanuele NV, Lawrence AM (1985) Management of type II diabetes mellitus Postgraduate Med 77:61–71

    CAS  Google Scholar 

  34. Fabrykant M (1958) Use of orinase as a basic adjuvant management of insulin-dependent diabetes. etabolism 7:213

    CAS  Google Scholar 

  35. Felber JP, Meyer HU, Curchod B, Maeder E, Pahud E, Jequier E (1981) Effect of 3-day fast on glucose storage and oxidation in obese hyperinsulinemic diabetics. Metabolism 30:184–189

    PubMed  CAS  Google Scholar 

  36. Feldmann JM, Lebovitz HE (1971) Endocrine and metabolic effects of glybenclamide. Evidence for an extrapancreatic mechanism of action. Diabetes 20:745

    Google Scholar 

  37. Ferner RE, Alberti KGM (1986) Why is there still disagreement over insulin secretion in noninsulin-dependent diabetes. Diabetic Med, Vol 3:13–17

    PubMed  CAS  Google Scholar 

  38. Gamba S, Campana M, Carlini M, Grassi G, Regis G, Bruni B (1982) Residual insulin secretion in diabetic patients treated firstly with sulphonylureas and then with insulin. Diabetologia 23:168

    Google Scholar 

  39. Gerö L, Koranyi L, Tamas Gy Jr (1982) Remission-like improvement in residual B-cell function of insulin treated type-II (non-insulin dependent) diabetics following the introduction of insulin therapy. Diabetologia 23:169

    Google Scholar 

  40. Gries FA, Toeller M (1977) Grundlagen der Diabetesdiät. Aktuel Ernähr 2:120

    Google Scholar 

  41. Groop L, Harno K, Tappanen E-M. (1984) The combination of insulin and sulfonylurea in the treatment of secondary drug failure in patients with type II diabetes. Acta endocrinologica 106:1–97

    Google Scholar 

  42. Groop L, Pelkonen R, Koskimies S (1982) The mechanisms of secondary drug failure in patients with type II (non-insulin-dependent) diabetes mellitus. Diabetologia 23:171

    Google Scholar 

  43. Hadden DR, Montgomery DAD, Skelly RJ, Trible ER, Weaver JAS, Wilson EA, Buchanan KD (1975) Maturity-onset diabetes mellitus: response to intensive dietary management. Brit Med J 3:276–278

    PubMed  CAS  Google Scholar 

  44. Hamelbeck H, Klein W, Zoltobrocki M, Schöffling K (1982) Glibenclamid/Insulin-Kombinationsbehandlung beim Sekundärversagen der Sulfonylharnstoff-Therapie. Dtsch Med Wschr 107

    Google Scholar 

  45. Haupt E (1983) Über die Grenzen der Anwendbarkeit und den Verlust der Wirksamkeit von blutzuckersenkenden Sulfonamiden in der Dauertherapie. 18. Jahres-Tg. d. Dtsch. Diabetes-Gesellschaft, Göttingen, 12.-14. Mai 1983

    Google Scholar 

  46. Haupt E, Laube F, Loy H, Schöffling K (1977) Neue Untersuchungen zum Sekundärversagen der Therapie mit Blutglukosesenkenden Sulfonamidderivaten. Med Klinik 72:1529

    CAS  Google Scholar 

  47. Henrichs HR (1983) Kombinierte Sulfonylharnstoff/Insulin-Therapie bei Diabetes mellitus nach Tabletten-sekundärversagen -praktisches klinisches Vorgehen. In: Bachmann W, Mehnert H (Hrsg) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, Basel, S 106

    Google Scholar 

  48. Henrichs HR, Bleicher-Ewe G, Marschall M, Schwarze B (1985) SH-Insulin-Kombination (SH-I) bei Diabetes mellitus nach Tablettensekundärversagen (TV) Ergebnisse einer Doppelblind-Glibenclamid-Cross over-Auslaßstudie. Act Endokr 6:88

    Google Scholar 

  49. Holman RR, Turner RC (1977) Diabetes, the quest for basal normoglycemia. Lancet 1:469–474

    PubMed  CAS  Google Scholar 

  50. Holman RR, Turner RC (1979) Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes. Diabetes 28:227–230

    PubMed  CAS  Google Scholar 

  51. Holman RR, Turner RC (1980) The basal plasma glucose: a simple relevant index of maturity-onset diabetes. Clin Endocr 14:279–286

    Google Scholar 

  52. Howe-Davies S, Simpson RW, Turner RC (1980) Control of maturity-onset diabetes by monitoring fasting blood glucose and body weight. Diabetes Care, Vol 3, No. 5:607–610

    PubMed  CAS  Google Scholar 

  53. Jahnke K (1981) Behandlung des Erwachsenen-Diabetes (Typ-II). Verh Dtsch Ges Inn Med 87:25–34

    PubMed  CAS  Google Scholar 

  54. Jahnke K, Jahnke KA, Reis HE (1976) Über die Regenerationsfáhigkeit der ß-Zellfunktion bei adipösen Diabetikern nach Gewichtsreduktion. Dtsch Med Wschr 101:73

    PubMed  CAS  Google Scholar 

  55. Jahnke KA, Reis HE, Jahnke K (1976) Beurteilung der ß-Zellenfunktion des Diabetikers durch Bestimmung der endogenen Insulinsekretion nach Glukose-Tolbutamidstimulation. Med Welt (NF) 27:2293

    CAS  Google Scholar 

  56. Jarett RJ, Keen H (1976) Hyperglycemia and diabetes mellitus. Lancet II: 1009

    Google Scholar 

  57. Jenkins DJA, Wolever TMS, Tailor RH et al. (1981) Glycemic index of foods: a physiological basis for carbohydrate exchanges. Am J Clin Nutr 34:362

    PubMed  CAS  Google Scholar 

  58. Jenkins DJA, Wolever TMS, Nineham R, Sarson DL, Bloom SR, Ahern J, Alberti KGMM, Hockaday TDR (1980) Improved glucose tolerance four hours after taking guar with glucose. Diabetologia 19:21

    PubMed  CAS  Google Scholar 

  59. Katzeff HL, Savage PJ, Barclay-White B, Nagulesparan M, Bennett PH (1985) C-Peptide measurement in the differentiation of type I and type II diabetes mellitus. Diabetologia 28:264–268

    PubMed  CAS  Google Scholar 

  60. Klein W (1983) Die Kombination Insulin/Glibenclamid bei Sekundärversagen der Sulfonylharnstofftherapie. In: Bachmann W, Mehnert H (Hrsg) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, Basel, S 117

    Google Scholar 

  61. Klujko J, Reiter J, Beischer W, Hrstka V, Schmidt FH (1984) Untersuchungen zum Wirkungsmechanismus der kombinierten Gabe von Glibenclamid und Insulin bei Typ-II-Diabetikern. Akt Endokr 5:97

    Google Scholar 

  62. Koller S, Pichl J, Volkholz HJ, Sailer D (1984) Kombinierte Insulin/Glibenclamid-Therapie bei Typ-II-Diabetes. Akt Endokr 5:97

    Google Scholar 

  63. Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olevsky JM (1984) The acute and chronic effects of sulfonylurea-therapy in type II diabetes subjects. Diabetes, Vol 33:346–354

    PubMed  CAS  Google Scholar 

  64. Kolterman O, Olevsky JM (1984) The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Diabetes Care, Vol 7 (Suppl 1): 81–88

    PubMed  CAS  Google Scholar 

  65. Kolterman OG, Griffin J, Olevsky JM (1982) Response to Glybenclamide is restored in confirmed secondary failure patients following 14 days of exogenous insulin therapy. Clin Res 30:397 A

    Google Scholar 

  66. Krall LP, Bradley RF (1962) “Secondary failures” in the treatment of the diabetes mellitus with tolbutamide and with phenformin. Diabetes 11 (Suppl):88

    Google Scholar 

  67. Krall LP, Chabot VA (1978) Oral Hypoglycemic agents update. Med Clin North Am 62:681

    PubMed  CAS  Google Scholar 

  68. Kromann H, Borch E, Gale EAM (1981) Unnecessary insulin treatment for diabetes. Brit Med J 283:386–388

    Google Scholar 

  69. Kunkel W, Haupt E, Fröhlich A, Schöffling K (1972) Der Einfluß einer Gewichtsreduktion auf Verlauf und Behandlung des Erwachsenendiabetes. Erfahrungen an 228 Patienten. Med Welt 23:679

    PubMed  CAS  Google Scholar 

  70. Kyllästinen M, Groop L (1982) Glibenclamide improves the glycaemic control in insulin-treated elderly diabetic patients. European Association for the Study of Diabetes. 18th Annual Meeting, Budapest, Abstract No. 182

    Google Scholar 

  71. Lahtela J, Arranta J, Sotaniemi EA (1985) Enzyme inducers improve insulin sensivity in non-insulin-dependent diabetic subjects. Diabetes 34:911–916

    PubMed  CAS  Google Scholar 

  72. Laube H (1983) Die Stellung von Enzyminhibitoren in der Diabetestherapie. Internistische Welt 1

    Google Scholar 

  73. Lipson LG, Lipson M (1984) The therapeutic approach to the obese maturity-onset diabetic patients. Arch ntern Med 114:135–138

    Google Scholar 

  74. Lotz N, Bachmann W, Mehnert H (1985) Vorzüge der Kombinationstherapie von Sulfonylharnstoff (SH) mit Insulin bei Typ-II-Diabetes mit „Sekundärversagen einer SH-Therapie“ (SSH). Akt Endokr 6:98

    Google Scholar 

  75. Lotz N, Sieger C, Bachmann W (1983) Kombinationstherapie von Glibenclamid plus Insulin bei Typ-II-Diabetes mit „Sekundärversagen“ einer Sulfonylharnstofftherapie. In: Bachmann W, Mehnert H (Hrsg) Kombinationstherapie Insulin/Sulfonylharnstoff. Karger, Basel, S 124

    Google Scholar 

  76. Lyons TJ, Kennedy L, Atkinson AB, Buchanan KD, Hadden DR, Weaver JA (1984) Predicting the need for Insulin Therapy in late onset (40–69 years) Diabetes mellitus. Nothern Ireland: 105–107

    Google Scholar 

  77. Mehnert H, Reisner E (1964) Untersuchungen zur Frage des sog. Spätversagens der Sulfonylharnstofftherapie. Dtsch Med Wschr 89:1378

    PubMed  CAS  Google Scholar 

  78. Mehnert H (1962) Clinical and experimental findings after five years treatment of diabetes with sulfonylureas. Diabetes 11 (Suppl): 80

    PubMed  Google Scholar 

  79. Muir A, Howe-Davies SA, Turner RC (1982) General practice care of non-insulin-dependent diabetes with fasting blood glucose measurements. Am J Med 73:637–640

    PubMed  CAS  Google Scholar 

  80. Nankervis J, Proitto J, Aitken P, Harewood M, Afford F (1982) Differential effects of insulin therapy on hepatic and peripheral Insulin sensitivity in type II (non-insulin-dependent) diabetes. Diabetologia 23:320–325

    PubMed  CAS  Google Scholar 

  81. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039

    Google Scholar 

  82. Nicholas VE, Lawrence AM (1985) Management of type II diabetes mellitus. Achieving optimum metabolic control. Postgrad Med 77 8:61–71

    Google Scholar 

  83. Olevsky JM, Reaven GM (1976) Effects of sulfonylurea therapy on insulin binding to mononuclear leucocytes of diabetic patients. Am J Med 60:89

    Google Scholar 

  84. Olevsky JM, Koltermann OG (1981) Mechanisms of insulin resistance in obesity and non-insulin-dependent (type II) diabetes. Am J Med Vol 70:151–168

    Google Scholar 

  85. Otto H (1985) Therapie des Diabetes mellitus: Einstellungskriterien und Erfolgskontrolle (Richtlinien d. Dtsch. Diabetes-Gesellschaft). Akt Endokrin u. Stoffw 6:148–149

    Google Scholar 

  86. Owens DR, Biggs PI, Shetty KJ, Wragg KG (1980) The effect of glibenclamid on the glucose and insulin profile in maturity onset diabetes following both acute and long term treatment. Diabete and Metabolisme 6:219–224

    PubMed  CAS  Google Scholar 

  87. Owens DR, Wragg KG, Schetty KT, Biggs PI, Davies CD (1979) Glibenclamide. Acute long-term response imn M.O. diabetes. Horm Metab Res 11:411

    PubMed  CAS  Google Scholar 

  88. Peacock I, Tattersall RB (1984) The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? Brit Med J 288:1956–1959

    CAS  Google Scholar 

  89. Pfeiffer MA, Halter JB, Porte DP (1981) Insulin secretion in diabetes mellitus. Am J Med Vol 70

    Google Scholar 

  90. Pfeiffer MA, Halter JB, Judzewitsch RG, Porte D (1984) Acute and chronic effects of sulfonylurea drugs on pancreatic islets function in man. Diabetes Care, Vol 7 (Suppl l):25–34

    Google Scholar 

  91. Pfeiffer EF, Raptis S, Schröder K-E (1974) Einmalige intravenöse Gliben-clamid-Glukose-Belastung als Vorhersagetest. Dtsch med Wschr 99:1281

    PubMed  CAS  Google Scholar 

  92. Pfeiffer EF, Schöff-ling K, Steigerwald H, Treser A, Otto M (1957) Das Problem des Sekundärversagens der oralen Diabetesbehandlung. Dtsch med Wschr 82:1528

    PubMed  CAS  Google Scholar 

  93. Pissarek D, Panzram G, Lundershausen R, Adolph W, Senf L (1980) Ergebnisse einer Intensivierung der Therapie des neuentdeckten Maturity-onset-Diabetes. Endokrinologie 75, 1:105–115

    PubMed  CAS  Google Scholar 

  94. Prince MJ, Olevsky JM (1980) Direct in vitro effects of a sulfonylurea to increase human fibroblast insulin receptors. J Clin Invest 66:608

    PubMed  CAS  Google Scholar 

  95. Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F (1977) Glukosidase inhibition. A new approach to the treatment of diabetes, obesity and hyperlipoproteinaemia. Naturwissenschaften 64:536

    PubMed  CAS  Google Scholar 

  96. Raptis S, Pfeiffer EF (1971) Sulfonylharnstoffe als orale Antidiabetika der 1. und 2. Generation. Therapiewoche 21:578

    CAS  Google Scholar 

  97. Reaven GM (1984) Insulin secretion and insulin action in non-insulin-dependent diabetes mellitus: Which defect is primary? Diabetes Care, Vol 7 (Suppl 1): 17–24

    PubMed  CAS  Google Scholar 

  98. Reitman JS, Vasquez B, Klimes I, Nagluesparan M (1984) Improvement of glucose homeostasis after exercise training in non-insulin-dependent diabetes. Diabetes Care, Vol 7, Nr. 5:434–441

    PubMed  CAS  Google Scholar 

  99. Rendell M (1983) C-Peptide levels as a criterion in treatment of maturity-onset-diabetes. J Clin Endocrinol Metab 57:1198–1206

    PubMed  CAS  Google Scholar 

  100. Riddle CM (1985) New tactics for type II diabetes: Regimens based on intermediate-acting insulin taken at bedtime. Lancet 1:192–195

    PubMed  CAS  Google Scholar 

  101. Rosak C, Schwarz O, Althoff P-H, Schöffling K, Schmidt FM (1985) Kombinierte Behandlung von Typ-II Diabetes mit Insulin und Glibenclamid nach Tablettensekundärversagen. DMW 110:1975–1980

    CAS  Google Scholar 

  102. Rupp WM, Barbosa JJ, Blackshear PJ, McCarthy HB, Rolde TD, Goldenberg FJ, Rubstein TG, Dorman FD, Buchwald H (1982) The use of an implantable insulin pump in the treatment of type II diabetes. New Engl J Med 307, 5:265–270

    PubMed  CAS  Google Scholar 

  103. Sachse G, Willms B (1979) Klinische Bedeutung der Serumbestimmung. Diagnose und Prognose bei drohendem Sekundärversagen der Sulfonylharnstofftherapie. Med Klinik 74:1635–1640

    CAS  Google Scholar 

  104. Sachse G, Maser E, Federlin K (1984) Kombinationstherapie mit Insulin und Sulfonylharnstoffen bei Sekundärversagen der Sulfonylharnstofftherapie? Dtsch med Wschr 109:419

    PubMed  CAS  Google Scholar 

  105. Sauer H (1985) Therapeutisches Vorgehen bei Sulfonylharnstoff-Sekundärversagen. Dtsch Med Wschr 110:27–30

    PubMed  CAS  Google Scholar 

  106. Scarlett JA, Gray RS, Griffin J, Olevsky JM, Kolterman OG (1982) Insulin treatment reverse the insulin resistance of type II diabetes melitus. Diabetes Care, Vol 5, Nr 4:353–363

    PubMed  CAS  Google Scholar 

  107. Simonsen D, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R, De Fronzo R (1984) Mechanism of improvement in glucose metabolism after chronic Glibenclamide therapy. Diabetes, Vol 33:838–844

    Google Scholar 

  108. Skyler JS (1984) Non-insulin-dependent diabetes mellitus: A clinical strategy. Diabetes Care 7 (Suppl 1): 118–129

    PubMed  Google Scholar 

  109. Sönksen PH, Lowy C, Perkins JR, Lim HS (1984) Non-insulin-dependent diabetes: 10 year outcome in relation to initial response to diet and subsequent sulfonylurea therapy Diabetes Care, Vol 7 (Suppl 1): 59–66

    PubMed  Google Scholar 

  110. Spaethe R, Otto H (1973) Veränderungen des Blutglukose und des Seruminsulins nach Verabfolgung verschiedener kohlenhydrathaltiger Nahrungsmittel. In: Jahnke K, Mehnert H (Hrsg) Metabolische und klinische Aspekte der Kohlenhydrate in der Ernährung. Kirchheim und G, Mainz, S 74

    Google Scholar 

  111. Schade DS, Eaton RP, Mitchell W, Ortega Th (1980) Glucose and insulin response to high carbohydrate meals in normal and maturity-onset diabetes subjects. Diabetes Care 3:242–244

    PubMed  CAS  Google Scholar 

  112. Schmidt FH (1983) Beeinflussen Sulfonylharnstoffe eine durch exogenes Insulin bewirkte Hemmung der Insulinsekretion? Vortragsmanuskript Insel Workshop, Homburg/Saar

    Google Scholar 

  113. Schneider SH, Amorosa LF, Khachadurian AK, Ruderman NB (1984) Studies on the mechanism of improved glucose control during regular exercise in type II (non-insulin-dependent) diabetes. Diabetologia 26:355–360

    PubMed  CAS  Google Scholar 

  114. Schöffling K, Mehnert H, Haupt E (1984) Behandlung mit Sulfonylharnstoffen. In: Mehnert H, Schöffling K (Hrsg) Diabetologie in Klinik und Praxis. Georg Thieme, Stuttgart New York

    Google Scholar 

  115. Schöffling K, Orale Diabetes-Therapie 1980. Aktuel Endokrinol 1:3

    Google Scholar 

  116. Schöffling K, Pfeiffer EF, Ditschuneit H, Federlin K, Wildberger H (1961) 5 Jahre Sulfonylharnstofftherapie des Diabetes mellitus. Med welt (Stuttgart) 16:827

    Google Scholar 

  117. Schwarz O, Rosak C, Althof TP-H, Schöffling K, v. Dahl K, Schmidt FH (1984) Doppelblinde, kontrollierte Cross-over-Studie zur Behandlung von Typ-II-Diabetikern mit Insulin und Glibenclamid. Akt Endokrin 5:122

    Google Scholar 

  118. Stout RW (1982) Hyperinsulinaemia as an independent risk factor for atherosclerosis. Int J Obesity 6 (Suppl 1): 111–116

    Google Scholar 

  119. Stratmann FW (1957) Über Spätversager bei der peroralen Diabetes-Therapie und bei kombinierter Behandlung. Med Klin 52:589

    CAS  Google Scholar 

  120. Strauzenberg SE, Haller H, Meyer H (1958) Beitrag zum Problem der Versagerfalle bei der peroralen Diabetestherapie. Münch med Wschr 100:1535

    PubMed  CAS  Google Scholar 

  121. Streja D, Boyko E, Rabkin SW (1981) Nutrition therapy in non-insulin-dependent diabetes mellitus. Diabetes Care 4:81–84

    PubMed  CAS  Google Scholar 

  122. Toeller M, Gries FA, Grünklee D, Koschinsky Th (1980) Diät: Basis der Diabetestherapie trotz wechselnder Empfehlungen. Therapiewoche 30:8369

    Google Scholar 

  123. Traumann KJ, Hösl W, Grom E, Wittemann G (1982) Kombination von Insulin und Sulfonylharnstoffen bei der Therapie des Diabetes mellitus vom Erwachsenen-Typ. Dtsch Med Wschr 107:180–184

    PubMed  CAS  Google Scholar 

  124. Trovati M, Carta Qu, Cavalot F, Vitali S, Banandi C, Lucchina PG, Focchi F, Emanuelli G, Lenti G (1984) Influence of Physical Training on Blood Glucose Control, Glucose Tolerance, Insulin Secretion, and Insulin Action in Non-Insulin-dependent Diabetes Patients. Diabetes Care 7:416–420

    PubMed  CAS  Google Scholar 

  125. Turner RC, McCarthy ST, Holmann RR, Harris E (1976) Betacell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1:1252–1254

    PubMed  CAS  Google Scholar 

  126. UK Prospective Study of Therapies of Maturity-Onset Diabetes (1983) 1. Effect of Diet, Sulphonylurea, Insulin or Bigua-nide Therapy of Fasting Plasma Glucose and Body Weight over one Year (a multicentre Study). Diabetologia 24:40–411

    Google Scholar 

  127. UK Prospective Diabetes Study (1985) II. Reduction in HbA 1C with basal Insulin Supplement, Sulphonylurea or Biguanide Therapy in Maturity-Onset Diabetes. Diabetes Care 34:793–798

    Google Scholar 

  128. Unger RH, Grundy (1985) Hyperglycemia as an inducer as well as a consequence of impaired isletcell function and insulin resistance: implications for the management of diabetes. Diabetologia 193:119–121

    Google Scholar 

  129. Vessby B, Boberg M, Karlström B, Lithell H, Werner I (1984) Improved metabolic control after supplemented fasting in overweight type II diabetic patients. Acta Med Scand 216:67–74

    PubMed  CAS  Google Scholar 

  130. Vigneri R, Gullo D, Pezzino V (1984) Metformin and Insulin Receptors. Diabetes Care 7:113

    PubMed  CAS  Google Scholar 

  131. Vigneri R, Pezzino V, Wong KY, Goldfìne ID (1982) Comarison of the in vitro effect of biguanides and sulfonylureides on insulin binding to its receptors in target cells. J Clin Endocrin Metab 54:95–100

    CAS  Google Scholar 

  132. Waldhäusl W, Ver-happer H, Bratusch-Marrain P Unterschiedliche Suppression der endogenen Insulinsekretion durch biosynthetisches Humaninsulin beim Menschen. 1. Internationales Symposium „Neue Insuline“, Freiburg/Breisgau

    Google Scholar 

  133. Wales JK (1982) Treatment of type 2 (non-insulin dependent) diabetics with diet alone. Diabetologia 23:240–245

    PubMed  CAS  Google Scholar 

  134. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D (1984) Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7, 5:491–502

    PubMed  CAS  Google Scholar 

  135. Welborn TA, Garcia-Webb P, Bonser AM (1981) Basal C-Peptide in the discrimination of type I diabetes from type II diabetes. Diabetes Care 4:616–619

    Google Scholar 

  136. Wilson RM, Van der Minne, Deverill I, Heller SR, Gelsthrop K, Reeves WG, Tattersell RB (1985) Insulin dependence: problems with the classification of 100 consecutive patients. Diabetic Med 2:167–172

    PubMed  CAS  Google Scholar 

  137. Wilson EA, Hadden DR, Merrett JD, Montgomery DA, Weaver JA (1980) Dietary management of maturity-onset diabetes. Br Med J 280:1367

    PubMed  CAS  Google Scholar 

  138. WHO (1980) Expert Committee on Diabetes mellitus. Second report. Technical Report Series 646. World Health Organization, Geneva

    Google Scholar 

  139. Zilker Th, Krönzlin Th, Schweigart U, Ermler R, Bottermann P (1976) Radioimmunologische Serumbestimmung beim manifesten Diabetes mellitus als Parameter der Therapieplanung. Med Klinik 71:761

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Endokrinologie des Zentrums der Inneren Medizin, Universitätsklinikum Frankfurt a. M, Deutschland

    P.-H. Althoff & C. Rosak

Authors
  1. P.-H. Althoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Rosak
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Humboldtstr. 14, D-6200, Wiesbaden, Deutschland

    Klaus Miehlke (ständigen Schriftführer) (ständigen Schriftführer)

Rights and permissions

Reprints and permissions

Copyright information

© 1986 J. F. Bergmann Verlag, München

About this paper

Cite this paper

Althoff, PH., Rosak, C. (1986). Die Differentialtherapie des Typ-II-Diabetes. In: Miehlke, K. (eds) Verhandlungen der Deutschen Gesellschaft für Innere Medizin. Verhandlungen der Deutschen Gesellschaft für Innere Medizin, vol 92. J.F. Bergmann-Verlag, Munich. https://doi.org/10.1007/978-3-642-85459-0_103

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85459-0_103

  • Publisher Name: J.F. Bergmann-Verlag, Munich

  • Print ISBN: 978-3-8070-0360-3

  • Online ISBN: 978-3-642-85459-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation